stockrowBioCryst Pharmaceuticals, Inc.
BCRX Healthcare Drug Manufacturers Specialty & Generic
BioCryst Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $874.8 million, up 94.1% from fiscal 2024.
- Revenue
- +13.1%
- EPS
- +150.0%
- Free cash flow
- −18.7%
- Total debt
- +15.2%
Quarter to September 2026, against a year earlier
Follow BCRX
Alert me
BioCryst Pharmaceuticals, Inc. (BCRX) Price to free cash flow
As of 5 November 2026, BioCryst Pharmaceuticals, Inc. (BCRX) trades at a price to free cash flow of 5.3×. Over the past ten years it has ranged from 0.0× (June 2025) to 120× (July 2025); the current reading is higher than 90% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 16.3× and below the Healthcare sector median of 21.1×.
Price to free cash flow, daily
Embed this chart
Annual newest first
| Period | Price to free cash flow | Change |
|---|---|---|
| FY2025 | 4.7× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | Price to free cash flow | Change |
|---|---|---|
| Sep 2026 | 5.8× | (14.60%) |
| Jun 2026 | 6.8× | (8.25%) |
| Mar 2026 | 7.4× | 56.52% |
| Dec 2025 | 4.7× | (85.78%) |
| 43 more quarters | Free account |
Against its own ten years
Price to free cash flow against peers
| Company | Price to free cash flow |
|---|---|
| ALVO Alvotech compare | n/m |
| RGC Regencell Bioscience Holdings Limited compare | n/m |
| HCM HUTCHMED (China) Limited Sponsored ADR compare | n/m |
| BCRX BioCryst Pharmaceuticals, Inc. | 5.3× |
| ANIP ANI Pharmaceuticals, Inc. compare | 7.3× |
| PBH Prestige Consumer Healthcare Inc. compare | 9.9× |
| TRLV Trulieve Cannabis Corp. compare | 11.8× |
| PRGO Perrigo Company plc compare | 12.4× |
| XERS Xeris Biopharma Holdings, Inc. compare | 32.2× |
| Drug Manufacturers Specialty & Generic industry median | 16.3× |
| Healthcare sector median | 21.1× |
| Market median | 14.1× |
What Price to free cash flow is
Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.
Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))
More on BCRX
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement